Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Stopped Terminated prior to completing enrollment goals due to COVID-related difficulties in recruiting patients

Conditions

• Parkinson Disease
• Dyskinesia, Drug-Induced
• Dyskinesias

Interventions

• DRUG: Dipraglurant
• DRUG: Placebo

Sponsor

Addex Pharma S.A.